6-[4-(1-Cyclohexyl-1 H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1 H)quinolinone (Cilostazol), a Phosphodiesterase Type 3 Inhibitor, Reduces Infarct Size via Activation of Mitochondrial Ca2+-Activated K+ Channels in Rabbit Hearts
Authors:
- Hirofumi NishidaHNHirofumi Nishida
- Toshiaki SatoTSToshiaki Sato
- Masaru MiyazakiMMMasaru Miyazaki
- Haruaki NakayaHNHaruaki Nakaya
- 1 July 2008
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 326 (1) , 100-104
Abstract
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 (PDE III) inhibitor, activates cAMP-dependent protein kinase A (PKA). The cAMP/PKA pathway potentiates the opening of mitochondrial Ca2+-activated K+ (mitoKCa) channels and confers cardioprotection. Although cilostazol has been reported to directly activate sarcolemmal large-conductance Ca2+-activated K+ channels, it remains unclear whether cilostazol modulates the opening of mitoKCa channels. Therefore, we tested the possibility that cilostazol opens mitoKCa channels and protects hearts against ischemia/reperfusion injury. Flavoprotein fluorescence in rabbit ventricular myocytes was measured to assay mitoKCa channel activity. Infarct size in the isolated perfused rabbit hearts subjected to 30-min global ischemia and 120-min reperfusion was determined by triphenyltetrazolium chloride staining. Cilostazol (1, 3, 10, and 30 μM) oxidized flavoprotein in a concentration-dependent manner. The oxidative effect of cilostazol (10 μM) was antagonized by the mitoKCa channel blocker paxilline (2 μM). Activation of PKA by 8-bromoadenosine 3′5′-cyclic monophosphate (0.5 mM) potentiated the cilostazol-induced flavoprotein oxidation. Treatment with cilostazol (10 μM) for 10 min before ischemia significantly reduced the infarct size from 67.2 ± 1.3 (control) to 33.6 ± 5.3% (p < 0.05). This infarct size-limiting effect of cilostazol was abolished by paxilline (60.3 ± 4.9%) but not by the PKA inhibitor (9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]-benzodiazocine-10-carboxylic acid hexyl ester (KT5720) (200 nM, 40.5 ± 3.5%). On the other hand, another PDE III inhibitor, milrinone (10 μM), neither oxidized flavoprotein nor reduced infarct size. Our results suggest that cilostazol exerts a cardioprotective effect via direct activation of mitoKCa channels.Keywords
This publication has 20 references indexed in Scilit:
- Infarct size limitation by adrenomedullin: protein kinase A but not PI3-kinase is linked to mitochondrial KCa channelsCardiovascular Research, 2008
- The Cardioprotective Effect of a Statin and Cilostazol Combination: Relationship to Akt and Endothelial Nitric Oxide Synthase ActivationCardiovascular Drugs and Therapy, 2007
- Mitochondrial Ion ChannelsAnnual Review of Physiology, 2007
- Cilostazol Suppresses Superoxide Production and Expression of Adhesion Molecules in Human Endothelial Cells via Mediation of cAMP-Dependent Protein Kinase-Mediated Maxi-K Channel ActivationThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Cardiac mitochondrial preconditioning by Big Ca2+-sensitive K+ channel opening requires superoxide radical generationAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- The role of β‐Adrenergic Receptor Signaling in CardioprotectionThe FASEB Journal, 2005
- Mitochondrial Ca 2+ -Activated K + Channels in Cardiac MyocytesCirculation, 2005
- Cytoprotective Role of Ca 2+ - Activated K + Channels in the Cardiac Inner Mitochondrial MembraneScience, 2002
- Paxilline Inhibition of the Alpha-subunit of the High-conductance Calcium-activated Potassium ChannelNeuropharmacology, 1996
- Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia.Stroke, 1989